Cart
sales@molnova.com
CHF6001
CAS No. 1239278-59-1
CHF6001( CHF-6001 | CHF 6001 )
Catalog No. M10961 CAS No. 1239278-59-1
A novel, highly potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC50 of 0.026 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 620 | Get Quote |
|
| 10MG | 885 | Get Quote |
|
| 25MG | 1314 | Get Quote |
|
| 50MG | 1773 | Get Quote |
|
| 100MG | 2385 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCHF6001
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel, highly potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC50 of 0.026 nM.
-
DescriptionA novel, highly potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC50 of 0.026 nM; inhibits PDE4 isoforms A-D with equal potency, 7- and 923-fold more potent than roflumilast and cilomilast, and displays >20,000-fold selectivity versus PDE4 compared with a panel of PDEs; effectively inhibits (subnanomolar IC50 values) the release of TNF-α from human PBMCs, THP-1, and rodent macrophages; inhibitsLPS-induced pulmonary neutrophilia (ED50=0.205 uM/kg) and leukocyte infiltration (ED50=0.188 uM/kg) in rats.COPD Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsCHF-6001 | CHF 6001
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE
-
Research AreaInflammation/Immunology
-
IndicationCOPD
Chemical Information
-
CAS Number1239278-59-1
-
Formula Weight687.533
-
Molecular FormulaC30H30Cl2F2N2O8S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(O[C@H](C1=CC=C(OC(F)F)C(OCC2CC2)=C1)CC3=C(Cl)C=[N+]([O-])C=C3Cl)C4=CC=C(NS(=O)(C)=O)C(OCC5CC5)=C4
-
Chemical Name(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Armani E, et al. J Med Chem. 2014 Feb 13;57(3):793-816.
2. Villetti G, et al .J Pharmacol Exp Ther. 2015 Mar;352(3):568-78.
3. Moretto N, et al. J Pharmacol Exp Ther. 2015 Mar;352(3):559-67.
4. Edwards MR, et al. Pharmacol Res Perspect. 2016 Jan 15;4(1):e00202.
molnova catalog
related products
-
Cilostazol
Cilostazol (OPC 13013, OPC 21) is a potent inhibitor of PDE3A with IC50 of 0.2 uM; inhibits platelet aggregation and has considerable antithrombotic effects in vivo.
-
BW-A78U
BW-A 78U is a PDE4 inhibitor (IC50: 3 μM). It is not inhibition on the lipopolysaccharide (LPS)-induced TNF-α release.
-
HT-0712
HT-0712 (IPL-455903) is a novel potent, selective PDE4 inhibitor with IC50 of 0.15 uM for PDE4D3.
